Introduction
============

Oral anticoagulation therapy (OAT) is the cornerstone of stroke prevention in nonvalvular atrial fibrillation (NVAF) \[[@B1]\]. Current registries of anticoagulation therapy (ACT) for NVAF are a priority in high-income countries \[[@B2][@B3]\]. However, in upper middle-income countries like Mexico, there is scarce epidemiological data about OAT for NVAF \[[@B4][@B5]\].

CARMEN-AF (Registry of Atrial Fibrillation and Embolic Risk in Mexico) is a nationwide, industry-independent registry, developed as a means to bridge the information gap about OAT for NVAF in Mexico \[[@B6]\]. Herein, we report the results of the CARMEN-AF Registry, analyzed by age, AF type, and thromboembolic risk.

Material and Methods
====================

CARMEN-AF is an ongoing, observational, longitudinal, multi-center, nationwide registry of OAT in NVAF in Mexico. A full list of the investigators of the Registry could be consulted in the Appendix A of this article. The protocol has already been published \[[@B6]\]. An English version of the Registry of Atrial Fibrillation and Embolic Risk in Mexico (CARMEN-AF) could be consulted in Supplementary Material. Mexico's economic status as an upper-middle income country is based on the 2013 World Bank Classification according to gross national income per capita \[[@B7]\]. A total of 1,423 consecutive patients were enrolled in a three-year period (September 19, 2014 -- December 18, 2017).

Study population
----------------

Eligible patients were at least 18 years old, with one or more risk factors for thromboembolism evaluated by CHA~2~DS~2~-VASc score and diagnosed with NVAF at least 6 months prior to their inclusion. Patients were included independent of anti-thrombotic therapy (ATT) (antiplatelet drugs \[APD\], vitamin K antagonists \[VKA\] or direct oral anticoagulants \[DOAC\] available in Mexico \[dabigatran, rivaroxaban, and apixaban\]). We used cross-sectional data obtained at patient recruitment. Physicians performed data collection at regular clinic visits using a paper-based case report form, with subsequent capture in an electronic case report form for data storage.

A table specifying the centers that participated, grouped by state (geographical distribution), and details about the type of clinic (public/private, second/third level), and the type of practice (the specialty of the center coordinator) can be consulted in the supplementary material. It also includes the type of residence of the patients (urban or rural). All patients were treated in urban centers (mostly by cardiologists), representing 29 states of the Mexican Republic. All patients were assessed at an initial clinical visit with a complete medical history and physical examination (Table [1](#T1){ref-type="table"}).

###### 

Geographical distribution (Mexican states) of subjects included in CARMEN-AF and other related variables.

  ---------------------------------------------------------------------------- --------------------- --------------- --------- ------------------------------ --------------------------------------------------------
  Center                                                                       State                 Level of care   Type      Specialty of the coordinator   Type of residency of the patients (Urban, rural, both)
                                                                                                                                                              
  Sociedad Cardiovascular de Aguascalientes                                    Aguascalientes        Third           Private   Electrophysiologist            Urban
  Hospital Hidalgo                                                             Aguascalientes        Third           Public    Cardiologist                   Both
  Hospital Regional No1 IMSS, Tijuana                                          Baja California       Second          Public    Cardiologist                   Both
  Hospital Angeles Tijuana                                                     Baja California       Third           Private   Cardiologist/Internist         Urban
  Plaza Medical                                                                Baja California       Third           Private   Cardiologist                   Urban
  Hospital General ISSSTE, La Paz                                              Baja California sur   Third           Public    Cardiologist/Internist         Urban
  Hospital GE 'Dr Javier Buenfil Osorio' INDESALUD                             Campeche              Third           Public    Cardiologist                   Both
  Instituto Nacional de Cardiologist 'Ignacio Chavez'                          Mexico City           Third           Public    Electrophysiologist            Both
  Hospital de Especialidades, Centro Medico Nacional 'La Raza' IMSS            Mexico City           Third           Public    Electrophysiologist            Both
  Hospital de Cardiologist del Centro Medico Nacional 'Siglo XXI' IMSS         Mexico City           Third           Public    Electrophysiologist            Both
  Hospital General de Mexico                                                   Mexico City           Third           Public    Electrophysiologist            Urban
  Instituto Nacional de Ciencias Medicas y Nutricion 'Salvador Zubiran'        Mexico City           Third           Public    Neurologist                    Urban
  CIMA Chihuahua                                                               Chihuahua             Third           Private   Cardiologist                   Urban
  Unidad Medica de Alta Especialidad No71 IMSS, Coahuila                       Coahuila              Third           Public    Cardiologist                   Urban
  Hospital General de Zona No 10, Manzanillo                                   Colima                Second          Public    Cardiologist/Internist         Urban
  Hospital General de Zona No 1 IMSS, Durango                                  Durango               Second          Public    Cardiologist/Internist         Both
  ISSEMYM Toluca                                                               Estado de Mexico      Third           Public    Electrophysiologist            Urban
  Hospital Angeles Leon                                                        Guanajuato            Third           Private   Electrophysiologist            Both
  Hospital General de Acapulco                                                 Guerrero              Third           Public    Cardiologist/Internist         Both
  Hospital General de Pachuca                                                  Hidalgo               Third           Public    Cardiologist/Internist         Both
  Hospital Civil de Guadalajara                                                Jalisco               Third           Public    Cardiologist/Internist         Urban
  Hospital General de Uruapan                                                  Michoacan             Second          Public    Cardiologist                   Both
  Instituto Nacional de Trasplantes                                            Morelos               Second          Private   Cardiologist/Internist         Urban
  Instituto de Cardiologist y Medicina Vascular Hospital Zambrano, Tec Salud   Nuevo Leon            Third           Private   Electrophysiologist            Urban
  Hospital Regional de Alta Especialidad de Oaxaca                             Oaxaca                Third           Public    Cardiologist. Internist        Urban
  Clinica Molina                                                               Oaxaca                Segunda         Public    Cardiologist                   Urban
  Hospital General del Sur de Puebla                                           Puebla                Third           Private   Electrophysiologist            Urban
  Hospital Angeles de Puebla                                                   Puebla                Third           Private   Electrophysiologist            Urban
  Instituto del Corazon Queretaro                                              Queretaro             Third           Private   Internist                      Both
  Hospital General de Zona No3 IMSS                                            Quintana Roo          Second          Public    Cardiologist                   Both
  Hospital Central 'Dr Ignacio Morones Prieto'                                 San Luis Potosi       Third           Public    Cardiologist                   Both
  Torre Medica Olivos                                                          San Luis Potosi       Primer          Private   Cardiologist                   Urban
  Hospital Civil de Culiacan                                                   Sinaloa                               Public    Cardiologist                   Both
  Angeles Culiacan                                                             Sinaloa               Third           Private   Cardiologist/Internist         Urban
  Hospital General de Culiacan                                                 Sinaloa               Second          Public    Cardiologist/Internist         Both
  Centro Medico Nacional del Noroeste IMSS                                     Sonora                Third           Public    Cardiologist                   Both
  Hospital Regional de Alta Especialidad 'Juan Graham Casasus'                 Tabasco               Third           Public    Cardiologist/Internist         Both
  Hospital Regional de PEMEX Ciudad Madero                                     Tamaulipas            Third           Public    Cardiologist                   Both
  Unidad Medica de Alta Especialidad No 14 IMSS                                Veracruz              Third           Public    Cardiologist                   Both
  Star Medica Merida                                                           Yucatan               Third           Private   Cardiologist                   Urban
  Hospital 'San Agustin'                                                       Zacatecas             Third           Private   Cardiologist                   Both
  ---------------------------------------------------------------------------- --------------------- --------------- --------- ------------------------------ --------------------------------------------------------

Statistical methodology
-----------------------

Data was analyzed using SPSS v. 22.0. Demographic differences among continuous variables with normal distribution were examined using Student's t-test; Wilcoxon signed-rank test was used when variables failed normality test. Categorical variables were analyzed using Chi-square test, either Fisher's exact test or Yates's correction for continuity. A 2-tail test with a *P* value \<0.05 was considered statistically significant.

Informed consent
----------------

Informed consent was obtained from each patient and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.

Results
=======

A total of 1,423 consecutive patients were enrolled in a three-year period (September 19, 2014--December 18, 2017). Mean age of participants was 69 ± 13 years old. 731 (51.4%) were male. Complete demographic characteristics are shown in Table [2](#T2){ref-type="table"}.

###### 

Demographic characteristics.

  ------------------------------- ---------------- --------------- ----------------- ----------
  Demographic characteristics                                                        
                                                                                     
                                  All(n = 1,423)   Male(n = 731)   Female(n = 692)   *P*\*
                                                                                     
  Gender (%)                                       51.4            48.6              ns
  Age, years ± SD                 69 ± 13          68 ± 13         70 ± 12           =0.002
  Weight, kg ± SD                 75 ± 16          80 ± 15         69 ± 14           \<0.0001
  Body Mass Index, kg/m^2^ ± SD   28.5 ± 5.0       28.4 ± 4.6      28.7 ± 5.4        ns
  ------------------------------- ---------------- --------------- ----------------- ----------

\* *P* value was obtained comparing Gender groups using Chi-square test and Student's t-test.

NVAF was paroxysmal in 37.3% of the cases, persistent in 22.1%, permanent in 40.6%; AF was asymptomatic in 59.4% of patients. The most prevalent comorbidities (Table [3](#T3){ref-type="table"}) in patients with NVAF were hypertension (72.5%), diabetes (28.4%), heart failure (23.6%) and smoking (16.4%).

###### 

Comorbidities of total population.

  -------------------------------- ----------------- ---------------- ------------------ ----------
  Comorbidities                                                                          
                                                                                         
  (%)                              All (n = 1,423)   Male (n = 731)   Female (n = 692)   *P*\*
                                                                                         
  Hypertension                     72.5              71.3             73.8               ns
  Diabetes                         28.4              31.3             25.3               =0.007
  Heart failure                    23.6              25.3             21.8               ns
  Smoking                          16.4              23.9             8.5                \<0.0001
  Alcoholism                       9.2               17.1             0.9                \<0.0001
  Nonischemic cardiomyopathy\*\*   8.9               10.3             7.5                =0.042
  Coronary Artery Disease          7.1               9.7              4.3                \<0.0001
  Obstructive sleep apnea          3.9               5.2              2.6                =0.008
  Peripheral artery disease        1.8               1.0              2.7                =0.010
  -------------------------------- ----------------- ---------------- ------------------ ----------

\* *P* value was obtained comparing Gender groups using Chi-square test and Student's t-test.

\*\* Hipertensive, Idiopathic, and restrictive.

Related to ATT, 16.6% of patients were not receiving any; 19.4% were receiving APD, and 63.9% of the patients were receiving oral anticoagulants (VKA = 416, 29.2%; DOAC = 493, 34.6%). OAT was either monotherapy (56.9%) or combined with one or two APD (7.2%) (Table [4](#T4){ref-type="table"}).

###### 

Antithrombotic therapy according to AF type.

  --------------------------------------------- ----------------- ---------------------- ---------------------- ---------------------
  Antithrombotic therapy according to AF type                                                                   
                                                                                                                
  (%) *P* = 0.037\*                             All (n = 1,423)   Paroxysmal (n = 531)   Persistent (n = 314)   Permanent (n = 578)
                                                                                                                
  Without treatment                             16.6              17.5                   15.9                   16.1
  Antiplatelet                                  19.4              22.4                   19.7                   16.4
  Anticoagulant                                 56.8              53.7                   54.1                   61.1
  Anticoagulant + Antiplatelet                  5.7               4.9                    8.9                    4.7
  Triple therapy                                1.5               1.5                    1.3                    1.7
  --------------------------------------------- ----------------- ---------------------- ---------------------- ---------------------

\* *P* value was obtained comparing Gender groups using Chi-square test and Student's t-test.

Antithrombotic therapy by AF type
---------------------------------

In accordance to AF type (paroxysmal, persistent, and permanent), suboptimal ATT (no ATT or just APD treatment) was observed in 40.3% of patients in the paroxysmal group, 35.7% in the persistent group, and 32.5% in the permanent group. There was a statistically significant difference between treatments when the groups were compared. (*P* = 0. 026) (Figure [1](#F1){ref-type="fig"}).

![Antithrombotic therapy by AF type (%).\
\* *P* value was obtained comparing AF type groups vs Treatment groups using Chi-square test.](gh-15-1-767-g1){#F1}

Antithrombotic therapy by thromboembolic risk
---------------------------------------------

The thromboembolic risk was assessed using CHA~2~DS~2~-VASc score (moderate risk = 1 point; high risk ≥2 points). No significant difference was observed on ATT between moderate and high thromboembolic risk subjects. Interestingly, inadequate ATT was observed in 36.4% of high thromboembolic risk patients: 20.1% were treated with APD and 16.3% did not receive any treatment (Figure [2](#F2){ref-type="fig"}).

![Antithrombotic therapy according to CHA~2~DS~2~-VASc risk (%).\
\* *P* value was obtained comparing Treatment groups vs CHA~2~DS~2~-VASc groups using Chi-square test.](gh-15-1-767-g2){#F2}

Antithrombotic therapy by age
-----------------------------

As the CHA~2~DS~2~-VASc score classifies thromboembolic risk according to age, patients were divided into three groups (Figure [3](#F3){ref-type="fig"}). In the group of patients younger than 65 years old, 70.4% received OAT (DOAC 34.2%, VKA 36.2%), 15.2% received APD and 14.3% did not receive ATT. In the 65--74 years old group, 66.4% of patients received OAT (DOAC 36.0%, AVKs 30.4%), 17.8% received APD, and 15.9% did not receive ATT. In the group of patients' ≥75 years old, 56.4% received OAT (DOAC 33.9.0%, VKA 22.5%), 24.5% were on APD, and 19.0% received no treatment.

![Antithrombotic therapy according to age (%).\
\* *P* value was obtained comparing Treatment groups vs Age groups using Chi-square test.](gh-15-1-767-g3){#F3}

Bleeding risk
-------------

There was a significant difference in HAS-BLED score between men and women; it was higher in men (1.82 ± 1.0 vs 1.71 ± 0.9; *P* = 0.032). According to bleeding risk, more women had a low risk of bleeding than men (9.7% vs 6.3%, *P* = 0.012), while more men had a high risk (20.8% vs 16.8%, *P* = 0.030) \[[@B19]\].

Of the studied population, 9.5% of women and 19.2% men at high risk of bleeding (HAS-BLED score = ≥3) did not receive any antithrombotic therapy (*P* = 0.021).

Discussion
==========

Patients with AF have 5 times greater risk of stroke than the general population \[[@B8]\]. There is significant evidence that the use of oral anticoagulants, both VKA and DOAC, reduce the risk of stroke in patients with NVAF \[[@B9][@B10][@B11][@B12]\]. Thromboembolic risk assessment should be performed at diagnosis using CHA~2~DS~2~-VASc score, and OAT should be started in patients with moderate and high risk of thrombosis (score ≥ 2) \[[@B1]\].

Clinical registries are proven to evaluate the correct application of treatment guidelines.

CARMEN-AF was designed to find out current information about the status of OAT for NVAF in Mexico. The main finding of this registry was that despite most of the patients in our cohort (85.6%) were classified as high thromboembolic risk according to CHA~2~DS~2~-VASc score (≥2), 35.8% of the total population diagnosed with NVAF were not receiving OAT or only received APD, a suboptimal therapy.

It was also found a trend in the use of OAT according to age. In Mexico, OAT is less commonly prescribed for elderly patients, despite that age is a well-known risk factor for thromboembolism; this conduct may be related to the fear of hemorrhagic complications in this group of patients according to HAS-BLED score \[[@B13]\]. Elderly patients who did receive OAT were more likely to be prescribed with a DOAC instead of VKA, probably due to better adherence and ease of use of DOAC \[[@B14]\].

Data collected by CARMEN-AF shows similarities with other large-scale NVAF registries. In Mexico, an upper middle-income country, hypertension remains the main comorbidity, just as in GLORIA-AF and GARFIELD registries. Also, the proportion of participants with high thromboembolic risk as assessed by CHA~2~DS~2~-VASc scores was very similar among the three registries (GLORIA-AF 86.1%; GARFIELD 84.3%; CARMEN-AF 85.6%). Finally, in Mexico DOAC are preferred as OAT in contrast with some other countries in Latin America, in which VKA remains the therapy of choice for prevention of thromboembolic complications in NVAF \[[@B15][@B16][@B17]\].

In order to understand differences among registries, we must remember that CARMEN-AF had a greater proportion of permanent NVAF (40.6%), while GLORIA-AF reported only 11.1% and GARFIELD 13.1% (*P* \< 0.0001). Also, the amount of patients left untreated in CARMEN-AF (16.6%) is greater than GARFIELD (12.3%) and GLORIA-AF (7.8%) global cohorts, as well as GLORIA-AF Latin America cohort (4.2%) \[[@B15], 16, [@B18]\]. Significant differences in treatment were observed between the three registries (*P* \< 0.0001).

Limitations
===========

CARMEN-AF was based on the prescription of antithrombotic therapy by different specialists; therefore, our data may not apply to other healthcare givers.

According to protocol, this survey recruited only patients with CHA2DS2-VASc≥ 1. Thus, no data on patients with score zero (low risk of stroke) were available.

Both patients and physicians knew they were participants of a registry; this might have led to higher overall anticoagulation rates compared with general population.

Unfortunately, the socioeconomic status as a variable is not available for the entire study.

Conclusions
===========

CARMEN-AF demonstrated a suboptimal thromboprophylaxis in NVAF in Mexico, an upper-middle income country, accounting for relevant differences with respect to high-income countries. Identification of gaps in the implementation of global guidelines between countries is the first step towards the objectives of the World Heart Federation Roadmap for NVAF.
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===============

The additional files for this article can be found as follows:

10.5334/gh.767.s1

###### 

Full list of the investigators and their participating centers of the Registry of Atrial Fibrillation and Embolic Risk in Mexico (CARMEN-AF).

10.5334/gh.767.s2

###### 

A full English version of the design of the Registry of Atrial Fibrillation and Embolic Risk in Mexico (CARMEN-AF), to assist our global audience to a better approaching to the original article published in Spanish in 2016 in Archivos de Cardiología de México.
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